Rational selection of virologic and immunological biomarkers and therapeutic endpoints in the clinical trials of new drugs treating chronic hepatitis B.
10.3760/cma.j.cn501113-20220327-00143
- Collective Name:Cooperative Group of Basic Research and Experimental Diagnosis of Liver Diseases, Chinese Society of Hepatology, Chinese Medical Association
- Publication Type:Journal Article
- MeSH:
Antiviral Agents/therapeutic use*;
Biomarkers;
DNA, Circular;
DNA, Viral;
Hepatitis B/drug therapy*;
Hepatitis B Surface Antigens;
Hepatitis B virus/genetics*;
Hepatitis B, Chronic;
Humans;
Virus Replication
- From:
Chinese Journal of Hepatology
2022;30(4):429-438
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV) infection remains to be the major cause of chronic liver diseases in China. Since the nucleos(t)ide analogues and pegylated interferon-alpha do not directly target the covalently closed circular DNA (cccDNA) in the nuclei of HBV-infected hepatocytes, those standard-of-care medications cannot efficiently cure the infected hepatocytes and rarely achieve the functional cure of chronic hepatitis B (CHB). Therefore, new antiviral drugs targeting distinct steps of HBV replication and immunotherapeutics reinvigorating antiviral immune responses are urgently needed for the functional cure of CHB. Based on the extensive discussion of the biological and clinical significance of new virologic biomarkers and distinct mechanism of drug candidates currently in clinical development, we propose that the selection of virologic and immunological biomarkers for evaluation of therapeutic efficacy as well as setting the therapeutic endpoints in the clinical trials should be based on the mode of action of investigational drugs. In addition, due to the complexity of CHB pathogenesis, selection of specific subpopulation of CHB patients for the clinical trials of drugs with a specific mode of action should also be considered.
